Last reviewed · How we verify

Praxbind — Competitive Intelligence Brief

Praxbind (IDARUCIZUMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Humanized Monoclonal Antibody Fragment [EPC]. Area: Metabolic.

marketed Humanized Monoclonal Antibody Fragment [EPC] dabigatran and its acylglucuronide metabolites Metabolic Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Praxbind (IDARUCIZUMAB) — Boehringer Ingelheim. Idarucizumab reverses dabigatran's anticoagulant effect by binding to it and its metabolites with high affinity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Praxbind TARGET IDARUCIZUMAB Boehringer Ingelheim marketed Humanized Monoclonal Antibody Fragment [EPC] dabigatran and its acylglucuronide metabolites 2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Humanized Monoclonal Antibody Fragment [EPC] class)

  1. Boehringer Ingelheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Praxbind — Competitive Intelligence Brief. https://druglandscape.com/ci/idarucizumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: